Wegovy Lowered Users' Heart Risks in New Trial
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Aug. 8, 2023 -- A large clinical trial weighing the medical merits of the obesity drug Wegovy (semaglutide) has unearthed a significant positive side effect. Taking the medication cut the risk for serious heart problems by 20 percent, drug maker Novo Nordisk announced Tuesday.
"People living with obesity have an increased risk of cardiovascular disease but, to date, there are no approved weight-management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death," Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a company news release.
According to Howard Weintraub, M.D., clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart in New York City, "There is now a drug that is well tolerated and safe from a cardiovascular perspective, that also lowers body weight in an effective manner. On top of all of this, there is significant reduction in the cumulative outcome of nonfatal myocardial infarction, cardiac death, and stroke."
"This is a very important study," Weintraub told HealthDay, "as no other weight loss medication has been shown to reduce cardiovascular events. It is likely that the beneficial impacts of this drug go above and beyond just weight loss. We were part of this important trial, and I think we all agree that this was a very important study."
However, Novo Nordisk did not share any additional details about exactly how the medication impacted weight loss or heart health, and the data have not yet been published in a peer-reviewed journal.
The trial results may help provide the evidence needed for insurance coverage of the medication. The drug's list price is $1,349 a month, and neither Medicare nor health insurance companies cover weight-loss medications, The New York Times reported. About 17,000 adults who were overweight or obese and had cardiovascular disease but not diabetes participated in the Novo Nordisk trial. Researchers tracked the incidence of heart attacks, strokes, and cardiovascular deaths during the five-year study period.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Some Environmental Stressors Linked to Increased Cardiovascular Risk
THURSDAY, June 13, 2024 -- Several climate change-related environmental stressors are associated with increased cardiovascular risk, according to a review published online June 12...
Sedentary Behaviors, Especially TV, Tied to Lower Odds of Healthy Aging
WEDNESDAY, June 12, 2024 -- Sedentary behaviors, especially watching television, are associated with reduced odds of healthy aging, according to a study published online June 11...
One in Five Children Globally Has Excess Weight
TUESDAY, June 11, 2024 -- One in five children or adolescents globally experience excess weight, according to a study published online June 10 in JAMA Pediatrics. Xinyue...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.